FDA approves ozanimod for treatment of multiple sclerosis

The FDA has approved a new drug named Ozanimod for the treatment of multiple sclerosis. Ozanimod binds to receptors in lymphocytes' surfaces, preventing them from reaching the brain. As the number of active lymphocytes decreases, the attack on the immune system diminishes.